FdaApplication
NDA 216158
Identifiers
- fda_app_no: NDA216158
Properties
| Property | Value |
|---|---|
| applicant_name | BRISTOL-MYERS SQUIBB CO |
| application_type | NDA |
| approval_date | 2024-09-26 |
Revenue by product
COBENFY
| Period | Revenue |
|---|---|
| Q2 2026 | $63.0M* |
| Q1 2026 | $56.0M* |
| Q4 2025 | $50.0M* |
| Q3 2025 | $43.0M* |
| Q2 2025 | $35.0M* |
| Q1 2025 | $27.0M* |
| Q4 2024 | $10.0M* |
| Q3 2024 | $0.0M* |
| Q2 2024 | $0.0M* |
| Q1 2024 | $0.0M* |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (3)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| COBENFY | TROSPIUM CHLORIDE; XANOMELINE TARTRATE | 20MG;EQ 50MG BASE | CAPSULE;ORAL |
| COBENFY | TROSPIUM CHLORIDE; XANOMELINE TARTRATE | 30MG;EQ 125MG BASE | CAPSULE;ORAL |
| COBENFY | TROSPIUM CHLORIDE; XANOMELINE TARTRATE | 20MG;EQ 100MG BASE | CAPSULE;ORAL |
3 products